India's pharma biz churns out wealth for country's richest

Biocon's Kiran Mazumdar-Shaw landed on Hurun India's Rich List.

Want to be a billionaire? If you're an Indian pharma entrepreneur, you're on the right track. The latest ranking of India's richest pegs the drug business as a powerful wealth creator, second only to the country's manufacturing sector.

Of the 100 wealthiest individuals on Hurun India's Rich List, 12 rose up via the pharma business. At No. 3, Dilip Shanghvi of Sun Pharmaceuticals was the highest-ranking drug baron, with $8.5 billion to his credit.

Cadila Healthcare's Pankaj Patel came in 20th with $2.8 billion, while Lupin's Desh Bandhu Gupta followed closely behind with $2.5 billion. Cyrus Poonawalla of Serum Pharma and Cipla's Yusuf Hamied both registered with $2.3 billion.

Six others topped $1 billion, including the founders of Dr. Reddy's Laboratories ($1.4 billion) and Glenmark Pharmaceuticals ($1.1 billion), both of which qualified for our Fastest-Growing Generics Companies ranking. But the fastest-growing pharma fortune belonged to Wockhardt's Habil Khorakiwala, whose wealth tripled. In fact, Khorakiwala's was the fastest-growing fortune on the list, period. Pharma also contributed to the list's richest self-made woman, Kiran Mazumdar-Shaw of Biocon.

- read the PharmaBiz story

Special Reports: Kiran Mazumdar-Shaw - The 25 most influential people in biopharma today | Kiran Mazumdar-Shaw - FierceBiotech's 2011 Women in Biotech | Top 11 Fastest-Growing Generics Companies

Related Articles:
CSL, Sun Pharma rank as absolutely fab in Asia
Ranbaxy's Singhs are $100M wealthier this year
 

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…